Stock LBIRD LUMIBIRD
Add to a list
To use this feature you must be a member
Log inSign up

LUMIBIRD Stock

Equities

LBIRD

FR0000038242

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris
Other stock markets
 11:35:11 2024-05-21 am EDT 		5-day change 1st Jan Change
12.9 EUR +0.78% Intraday chart for LUMIBIRD -2.27% +5.91%
May. 03 Lumibird launches product for dry eyes CF
Apr. 23 Lumibird: over 7% growth in quarterly sales CF
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 224M 243M Sales 2025 * 244M 265M Capitalization 283M 307M
Net income 2024 * 15M 16.28M Net income 2025 * 19M 20.62M EV / Sales 2024 * 1.58 x
Net Debt 2024 * 71.7M 77.83M Net Debt 2025 * 55.65M 60.41M EV / Sales 2025 * 1.39 x
P/E ratio 2024 *
19.1 x
P/E ratio 2025 *
14.6 x
Employees 989
Yield 2024 *
-
Yield 2025 *
-
Free-Float 40.23%
More Fundamentals * Assessed data

Chart LUMIBIRD

Dynamic Chart

Latest news about LUMIBIRD

Lumibird launches product for dry eyes CF
Lumibird: over 7% growth in quarterly sales CF
Lumibird: EBITDA improved by 10% in 2023 CF
Lumibird SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lumibird: two orders from Saab for OdiPro CF
Lumibird: the stock outperforms after a positive note CF
Lumibird: sales up by almost 7% in 2023 CF
The LUMIBIRD Group Reports Unaudited Consolidated Sales Results for the Fourth Quarter and Full Year Ended 31 December 2023 CI
Lumibird: heavy decline after target adjustment CF
Lumibird: towards a technological partnership for Cilas CF
Lumibird: HoloDoppler project subsidized by Bpifrance CF
Lumibird: 11% rise in nine-month sales CF
Lumibird SA Provides Revenues Guidance for the Fourth Quarter and Full Year 2023 CI
Lumibird SA Reports Unaudited Consolidated Revenue Results for the Third Quarter and Nine Months of 2023 CI
Lumibird: surrounded after its half-year results CF
More news

Press releases LUMIBIRD

LUMIBIRD MEDICAL OBTAINS CE MARKING FOR C.DIAG®, A PLATFORM TO HELP DIAGNOSE DRY EYE GL
LUMIBIRD MEDICAL OBTAINS CE MARKING FOR C.DIAG®, A PLATFORM TO HELP DIAGNOSE DRY EYE AQ
LUMIBIRD: PUBLICATION OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE ANNUAL FINANCIAL REPORT GL
LUMIBIRD: ACCESS TO PREPARATORY DOCUMENTS FOR THE COMBINED GENERAL MEETING ON APRIL 29, 2024 GL
LUMIBIRD: ANNUAL RESULTS 2023 GL
More press releases

News in other languages on LUMIBIRD

LUMIBIRD : Capital Market Day 2024 – Présentation
LUMIBIRD : ASSEMBLEE GENERALE MIXTE DU 29 AVRIL 2024 : RESULTATS DES VOTES
LUMIBIRD : nombre d'actions au 30 avril 2024
Lumibird : un produit lancé pour la sécheresse oculaire
Chez Apple on n'a pas de croissance, mais on a des sous
More news

Quotes and Performance

1 day+0.78%
1 week-2.27%
Current month+3.61%
1 month-7.86%
3 months-4.02%
6 months-1.53%
Current year+5.91%
More quotes

Highs and lows

1 week
12.75
Extreme 12.75
13.30
1 month
12.20
Extreme 12.2
14.40
Current year
10.40
Extreme 10.4
15.48
1 year
10.40
Extreme 10.4
16.00
3 years
10.40
Extreme 10.4
24.35
5 years
5.40
Extreme 5.4
24.35
10 years
5.40
Extreme 5.4
24.35
More quotes

Managers and Directors - LUMIBIRD

Managers TitleAgeSince
Marc Paul Marcel Le Flohic CEO
 Chief Executive Officer 61 16-11-17
Sonia Rutnam DFI
 Director of Finance/CFO - 22-11-30
Nomblot-Gourhand Aude DFI
 Director of Finance/CFO - 18-09-30
Members of the board TitleAgeSince
Marc Paul Marcel Le Flohic CEO
 Chief Executive Officer 61 16-11-17
Marie-Begoña Lebrun BRD
 Director/Board Member - 16-04-04
Jean-François Coutris BRD
 Director/Board Member - 16-11-17
More insiders

Quotes

Date Price Change Volume
24-05-21 12.9 +0.78% 3 888
24-05-20 12.8 -2.66% 3,514
24-05-17 13.15 +0.77% 8,625
24-05-16 13.05 -0.38% 3,670
24-05-15 13.1 -0.76% 2,203

Real-time Euronext Paris, May 21, 2024 at 11:35 am EDT

More quotes

Company Profile

LUMIBIRD figure parmi les plus grands spécialistes mondiaux du laser. Fort de 50 années d'expérience et maîtrisant les technologies de laser à solides, de diodes laser et de laser à fibres, LUMIBIRD conçoit, fabrique et distribue des lasers haute performance à usages scientifiques (laboratoires de recherche et universités), industriels (production, défense/spatial, capteurs Lidar) et médical (ophtalmologie).
Sector
Advanced Medical Equipment & Technology
Calendar
06:30am - Capital Markets Day
More about the company

Income Statement Evolution

More financial data

Ratings for LUMIBIRD

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.8 EUR
Average target price
17.75 EUR
Spread / Average Target
+38.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
LUMIBIRD Stock LUMIBIRD
+5.91% 307M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+11.00% 227B
DANAHER CORPORATION Stock Danaher Corporation
+15.24% 198B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+17.99% 142B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+31.33% 111B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.56% 64.16B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+18.24% 54.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+5.12% 51.41B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+10.74% 45.32B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+5.55% 37.32B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. LBIRD Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW